Incyte Corp- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 Incyte Corp 公司

Incyte Corporation 是一家生物制药公司，专注于发现、开发和商业化治疗药物。该公司在两个治疗领域开展业务。一个治疗领域是血液学/肿瘤学，包括骨髓增生性肿瘤和移植物抗宿主病，以及实体瘤和血液系统恶性肿瘤。其另一个治疗领域是炎症和自身免疫，包括其皮肤病商业特许经营权。其血液学和肿瘤学特许经营权包括六种产品，即 JAKAFI (ruxolitinib)、MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab)、PEMAZYRE (pemigatinib)、ICLUSIG (ponatinib)、NIKTIMVO (axatilimab-csfr) 和 ZYNYZ (retifanlimab-dlwr)，以及众多临床开发项目。该公司的产品线还包括两种一流的 Mas 相关 G 蛋白偶联受体（MRGPRX2）小分子拮抗剂和口服 MRGPRX4 拮抗剂 INCB000547。

公司简介

公司代码INCY

公司名称Incyte Corp

上市日期Dec 06, 1993

CEOMr. Bill Meury

员工数量2617

证券类型Ordinary Share

年结日Dec 06

公司地址1801 Augustine Cut-Off

城市WILMINGTON

上市交易所NASDAQ Global Select Consolidated

国家United States of America

邮编19803

电话13024986700

网址https://www.incyte.com/

公司代码INCY

上市日期Dec 06, 1993

CEOMr. Bill Meury

公司高管

名称

名称/职务

职务

持股

持股变动

Mr. Herve Hoppenot

Director

1.62M

-3.14%

Mr. Julian C. Baker

Independent Chairman of the Board

278.77K

--

Mr. Paul J. Clancy

Independent Director

146.88K

+2.00%

Mr. Jean-Jacques Bienaime ,

Independent Director

144.77K

+1.77%

Mr. Michael James Morrissey

Executive Vice President, Head - Global Technical Operations

86.16K

+5.70%

Dr. Katherine A. High, M.D.

Independent Director

66.08K

+3.96%

Dr. Otis W. Brawley, M.D.

Independent Director

50.10K

+5.29%

Dr. Susanne Schaffert, Ph.D.

Independent Director

37.95K

+4.60%

Dr. Pablo J. Cagnoni

President - Research and Development

35.48K

+62.39%

Mr. Lee Heeson

Executive Vice President - Incyte, International

32.78K

+23.94%

名称

名称/职务

职务

持股

持股变动

Mr. Herve Hoppenot

Director

1.62M

-3.14%

Mr. Julian C. Baker

Independent Chairman of the Board

278.77K

--

Mr. Paul J. Clancy

Independent Director

146.88K

+2.00%

Mr. Jean-Jacques Bienaime ,

Independent Director

144.77K

+1.77%

Mr. Michael James Morrissey

Executive Vice President, Head - Global Technical Operations

86.16K

+5.70%

Dr. Katherine A. High, M.D.

Independent Director

66.08K

+3.96%

收入明细

单位: USD更新时间: 7月6日周日

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

业务USD

名称

营收

占比

JAKAFI revenues

709.41M

67.38%

OPZELURA revenues

118.70M

11.27%

JAKAVI product royalty revenues

92.14M

8.75%

OLUMIANT product royalty revenues

30.80M

2.93%

MINJUVI revenues

29.55M

2.81%

其他

72.28M

6.87%

暂无数据

业务

地区

业务USD

名称

营收

占比

JAKAFI revenues

709.41M

67.38%

OPZELURA revenues

118.70M

11.27%

JAKAVI product royalty revenues

92.14M

8.75%

OLUMIANT product royalty revenues

30.80M

2.93%

MINJUVI revenues

29.55M

2.81%

其他

72.28M

6.87%

股东统计

更新时间: 8月15日周五

持股股东

股东类型

持股股东

占比

Baker Bros. Advisors LP

15.74%

The Vanguard Group, Inc.

10.27%

Dodge & Cox

7.47%

BlackRock Institutional Trust Company, N.A.

5.99%

State Street Global Advisors (US)

5.06%

其他

55.47%

持股股东

占比

Baker Bros. Advisors LP

15.74%

The Vanguard Group, Inc.

10.27%

Dodge & Cox

7.47%

BlackRock Institutional Trust Company, N.A.

5.99%

State Street Global Advisors (US)

5.06%

其他

55.47%

股东类型

持股股东

占比

Investment Advisor/Hedge Fund

38.13%

Investment Advisor

36.41%

Hedge Fund

20.87%

Pension Fund

2.96%

Research Firm

2.54%

Individual Investor

2.18%

Bank and Trust

1.48%

Sovereign Wealth Fund

0.78%

Family Office

0.26%

机构持股

更新时间: 7月1日周二

报告期

机构数

持股数

持股占比

持股变动

2025Q2

1423

201.60M

103.23%

-197.50K

2025Q1

1457

199.01M

102.81%

-12.15M

2024Q4

1448

191.80M

99.11%

-19.23M

2024Q3

1401

192.85M

100.02%

-35.92M

2024Q2

1385

209.06M

108.78%

-39.98M

2024Q1

1357

227.85M

101.54%

-21.15M

2023Q4

1323

228.89M

102.19%

-14.49M

2023Q3

1300

224.25M

100.13%

-17.63M

2023Q2

1306

220.30M

98.76%

-17.67M

2023Q1

1294

227.74M

102.15%

-615.23K

股东持股明细

名称

持股数

占比

持股变动

变动比例

公告日期

Baker Bros. Advisors LP

30.49M

15.75%

+984.00

+0.00%

Jun 30, 2025

The Vanguard Group, Inc.

19.91M

10.29%

+403.13K

+2.07%

Mar 31, 2025

Dodge & Cox

14.86M

7.68%

-55.30K

-0.37%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

11.92M

6.16%

+257.27K

+2.21%

Mar 31, 2025

State Street Global Advisors (US)

10.04M

5.18%

+4.32K

+0.04%

Mar 31, 2025

AQR Capital Management, LLC

6.74M

3.48%

+3.23M

+92.31%

Mar 31, 2025

Geode Capital Management, L.L.C.

4.21M

2.17%

+167.91K

+4.16%

Mar 31, 2025

Renaissance Technologies LLC

3.71M

1.92%

-377.20K

-9.23%

Mar 31, 2025

LSV Asset Management

3.64M

1.88%

+170.48K

+4.92%

Mar 31, 2025

Invesco Capital Management LLC

2.74M

1.42%

+98.11K

+3.71%

Mar 31, 2025

持股ETF

更新时间: 8月2日周六

机构名称

占比

iShares Genomics Immunology and Healthcare ETF

4.03%

First Trust NYSE Arca Biotechnology Index Fund

3.76%

Invesco Biotechnology & Genome ETF

2.77%

SPDR S&P Biotech ETF

2.41%

Bushido Capital US Equity ETF

2.11%

VanEck Biotech ETF

2.07%

Strategas Global Policy Opportunities ETF

1.91%

Virtus LifeSci Biotech Products ETF

1.9%

Invesco S&P 500 Equal Weight Health Care ETF

1.64%

ROBO Global Healthcare Technology & Innovation ETF

1.6%

iShares Genomics Immunology and Healthcare ETF

占比4.03%

First Trust NYSE Arca Biotechnology Index Fund

占比3.76%

Invesco Biotechnology & Genome ETF

占比2.77%

SPDR S&P Biotech ETF

占比2.41%

Bushido Capital US Equity ETF

占比2.11%

VanEck Biotech ETF

占比2.07%

Strategas Global Policy Opportunities ETF

占比1.91%

Virtus LifeSci Biotech Products ETF

占比1.9%

Invesco S&P 500 Equal Weight Health Care ETF

占比1.64%

ROBO Global Healthcare Technology & Innovation ETF

占比1.6%

分红派息

近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股

公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

Incyte Corp

86.530USD

Incyte Corp

86.530

概览

公司

财务

分析